Brochure sent to prospective licensees promoting EcoNail

Brochure sent to prospective licensees promoting EcoNail

Brochure promoting MacroChem's topical testosterone to prospective licensees

Brochure promoting MacroChem's topical testosterone to prospective licensees

Special AAPS meeting version of SEPA brochure used to promote platform absorption technology

Special AAPS meeting version of SEPA brochure used to promote platform absorption technology

MacroChem Experience

Mel (second from left) with heads of ESSIR meeting in Rome, in Topiglan exhibit

Mel (second from left) with heads of ESSIR meeting in Rome, in Topiglan exhibit

European urologists visiting Topiglan exhibit at Geneva EAU meeting

European urologists visiting Topiglan exhibit at Geneva EAU meeting

MacroChem is a formerly NASDAQ-listed specialty pharmaceutical company that used novel drug delivery technologies to develop pharmaceutical products to treat important medical conditions. Over its more than 20 year history, its clinical stage products included Topiglan®, to treat erectile dysfunction, Benefen ™, to treat local pain, Opterone®, to treat male hypogonadism, and EcoNail ™, to treat fungal infection of the nail.*

From October 2000 through November 30, 2005, Mel Snyder was vice president of market development. He accepted his position with MacroChem after more than a year as consulting director of business development.

As consultant and VP, Mel believed that a company attempting to outlicense its compounds and technology should treat them like products – and thus, should employ all the communications techniques traditionally used in business-to-business marketing. In that effort, he...

  • Formulated well–documented licensing–support programs — brochures, PowerPoint presentations, medical and industry convention exhibits and PR programs — for company's proprietary enhancer, SEPA®, and its portfolio of SEPA-supplemented products:
  • Topiglan®, a topical treatment for erectile dysfunction
  • Benefen™, a topical treatment for localized pain
  • EcoNail™, a topical treatment for fungal infection of the toenails
  • Opterone®, a topical testosterone for male testosterone deficiency.
  • Mobilized company development, clinical and regulatory specialists into a credible presentation team, so that prospective licensees and investors better appreciated MacroChem capability to commercialize its platform and products.
  • Increased KOL (key opinion leader) awareness and support for MacroChem's technology and products by developing and staffing exhibits at scientific meetings like the American Urological Society, Endocrine Society, European Association for Urology, American College of Physicians, European Society for Sexual & Impotence Research, Drug Delivery Partnerships meetings, and other medical and industry groups.
  • Developed CD-video clips of investigators explaining rationale for early-stage products. He wrote annual reports, and arranged for MacroChem participation in a 2004 symposium in France, from which he Wrote and produced a 36-page monograph highlighting MacroChem technology.
  • Successfully persuaded an international pharma company to invest more than $1 million into a Phase 1 pharmacokinetics trial in exchange for a licensing option potentially worth more than $10 million in up-front through premarketing milestone payments, and $80 million in potential 5-year royalty payments.
  • Signed research collaborations with Pfizer and Novartis to test proprietary drugs from those companies when combined with MacroChem's enhancer.
  • Researched and produced the PowerPoint presentation to FDA's Carcinogenicity Assessment Committee following Agency's imposition of clinical hold. Following that presentation, the clinical hold was lifted.
  • Served as a spokesperson and speaker for topical medications (versus solid dosage forms, transdermal patches) in trade media and before drug-delivery and investment banking audiences. Presented before IIR, CBI, SMi symposia on drug delivery, MassBio. He authored a 2002 paper in Pharmaceutical Formulation & Quality, coauthored 2003 paper for European Pharmaceutical Contractor, and authored a 2003 Scrip insert. He created scientific posters for investigators.
EcoNail exhibit at Las Vegas dermatology meeting where Dr. Maibach announced his key study findings

EcoNail exhibit at Las Vegas dermatology meeting where Dr. Maibach announced his key study findings

MacroChem exhibit at American Association of Pharmaceutical Scientists meeting

MacroChem exhibit at American Association of Pharmaceutical Scientists meeting

*On August 31, 2005, MacroChem terminated substantially all its non- management personnel. At the direction of its board of directors, MacroChem discontinued all research and product development, and was directed to seek to sell the business or its assets. The company subsequently raised new financing, and is now reorganizing to move forward selected products as a bulletin-board listed company.